<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516255</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1644</org_study_id>
    <nct_id>NCT01516255</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Heart Frequency in Healthy Volunteers</brief_title>
  <official_title>A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). The aim of this trial is to&#xD;
      investigate if liraglutide effects the QTc interval. Moxifloxacin (AveloxÂ®) is administered&#xD;
      as positive control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum time-matched mean difference between the baseline subtracted QTci intervals</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc at liraglutide tmax (time to reach maximum concentration)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage subjects with QTc at least 450, 480 and 500 milliseconds</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin maximum time-matched mean change QTc and QTci</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration of liraglutide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax of liraglutide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitals signs: Blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: Pulse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial electrocardiography</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Double-blind / liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind / placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label / moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label / placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences</description>
    <arm_group_label>Double-blind / liraglutide</arm_group_label>
    <arm_group_label>Double-blind / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Injected subcutaneously. Subjects are randomly allocated to two treatment sequences</description>
    <arm_group_label>Double-blind / liraglutide</arm_group_label>
    <arm_group_label>Double-blind / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control</description>
    <arm_group_label>Open-label / moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered</description>
    <arm_group_label>Open-label / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>electrocardiogram (ECG)</intervention_name>
    <description>24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide</description>
    <arm_group_label>Double-blind / liraglutide</arm_group_label>
    <arm_group_label>Double-blind / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>electrocardiogram (ECG)</intervention_name>
    <description>Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected</description>
    <arm_group_label>Open-label / moxifloxacin</arm_group_label>
    <arm_group_label>Open-label / placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Fasting plasma glucose within normal limits (80-100 mg/dl)&#xD;
&#xD;
          -  BMI (Body Mass Index): 20.0-29.0 kg/m^2 (inclusive)&#xD;
&#xD;
          -  Heart rate within the range of 50-90 beats per minute (inclusive)&#xD;
&#xD;
          -  Subject is judged to be in good health on the basis of their medical history, physical&#xD;
             examination, ECG (electrocardiogram), and routine laboratory data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant disease history, in the opinion of the investigator, of&#xD;
             systemic or organ disease&#xD;
&#xD;
          -  Any clinically significant disease history, in the opinion of the investigator, of&#xD;
             cardiovascular disease&#xD;
&#xD;
          -  Clinically significant abnormalities on any pre-study clinical examination or any&#xD;
             abnormal laboratory measurements during screening&#xD;
&#xD;
          -  A family history of sudden cardiac death at age less than 50 years old&#xD;
&#xD;
          -  T-wave abnormalities&#xD;
&#xD;
          -  Individual or familial history of long QT Syndrome&#xD;
&#xD;
          -  Positive results on Screening for Hepatitis B surface antigen, Hepatitis C antibody or&#xD;
             HIV (human immunodeficiency virus) antibody&#xD;
&#xD;
          -  Positive results on the urine drug and alcohol screen&#xD;
&#xD;
          -  Any regular use of prescription or nonprescription drugs or vitamins and&#xD;
             herbal/nutritional supplements that cannot be stopped at screening&#xD;
&#xD;
          -  Any strenuous exercise (as judged by the investigator) from 4 days prior to&#xD;
             randomisation and during the entire trial period&#xD;
&#xD;
          -  Blood donation, trauma or surgery with blood loss exceeding 500 ml within the last 2&#xD;
             months prior to dosing&#xD;
&#xD;
          -  Subject is a smoker, occasional smoker or has a history of smoking (or use of any&#xD;
             tobacco) within the last 3 months&#xD;
&#xD;
          -  Excessive use of methylxanthine-containing beverages (more than 8 cups/day of coffee,&#xD;
             tea, soda or chocolate)&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding, intend to become pregnant within the next 3&#xD;
             months, or who are judged to be using inadequate contraceptive measures&#xD;
&#xD;
          -  A history (within the last 2 years) of drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol. 2009 Nov;49(11):1353-62. doi: 10.1177/0091270009339189. Epub 2009 Sep 8.</citation>
    <PMID>19737980</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

